The anthropometric characteristics in the two groups were not significantly different.



Similar documents
AMERICAN VENOUS FORUM

Beaumont Hospital. Varicose Veins. and their TREATMENT. Professor Austin Leahy, MCh, FRCS, FRCSI

Peninsula Commissioning Priorities Group. Commissioning Policy Varicose Vein Referral

Baby Your Legs! Get relief for: Heavy, tired or aching legs Swollen ankles and feet Varicose or spider veins. Managing leg health during pregnancy

TREATMENT OF VARICOSE VEINS: CAN IT BE IMPROVED BY MECHANOCHEMICAL ABLATION USING THE CLARIVEIN DEVICE?

Medicare C/D Medical Coverage Policy

LOWER EXTREMITY VENOUS DUPLEX ULTRASOUND:

X-Plain Varicose Veins Reference Summary

Confirmed Deep Vein Thrombosis (DVT)

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

PROVIDER POLICIES & PROCEDURES

Tired, Aching Legs? Swollen Ankles? Varicose Veins? An informative guide for patients

Medicare C/D Medical Coverage Policy

Provided by the American Venous Forum: veinforum.org

Recurrent Varicose Veins

Summary ID# Clinical Study Summary: Study F3Z-JE-PV06

A Guide to Healthier Legs

SYNOPSIS. Risperidone: Clinical Study Report CR003274

Non-surgical treatment of severe varicose veins

TREATMENT OF VARICOSE AND SPIDER VEINS Patient Info

SCRIPT NUMBER 122 VARICOSE VEINS - 2 (TWO SPEAKERS)

Clinical Study Synopsis

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

treatment of varicose and spider veins patient information SAMPLE a publication by advancing vein care

Tired legs, varicose veins

Graduated compression hosiery (stockings)

Varicose Veins Operation. Patient information Leaflet

2.0 Synopsis. Vicodin CR (ABT-712) M Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:

LONG TERM FOLLOW-UP AFTER ENDOVENOUS LASER ABLATION

Yes when meets criteria below

Information for patients who require Foam Sclerotherapy for Varicose Veins.

MEDICAL COVERAGE POLICY. SERVICE: Varicose Veins of the Lower Extremities. PRIOR AUTHORIZATION: Required.

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

University of Huddersfield Repository

Rapid Critical Appraisal of Controlled Trials

FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES

Venous Reflux Disease and Current Treatments VN20-87-A 01/06

Medical Coverage Policy Treatment for Varicose Veins-PREAUTH

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Endovenous Laser Therapy

Col league. SMMC Vascular Center Opens A PUBLICATION FOR SOUTHERN MAINE PHYSICIANS

LASER TREATMENT FOR VARICOSE VEINS

Re: LUMIGAN 0.03% (bimatoprost ophthalmic solution 0.03%) and LUMIGAN 0.01% (bimatoprost ophthalmic solution 0.01%)

The veins of the lower limbs can be subdivided into three subtypes: deep veins, superficial veins, and connecting veins (figure 1).

Varicose veins and spider veins

Tired, Aching Legs? Swollen Ankles? Varicose Veins?

Provided by the American Venous Forum: veinforum.org

Surgical Options for Venous Disease. Sandra C Carr MD Vascular Surgery Meriter Wisconsin Heart

CHAPTER 15 SCLEROTHERAPY FOR VENOUS DISEASE

Varicose Veins and Spider Veins

EndoVenous Laser Therapy (EVLT) Information Booklet. Dr. Dueck. Varicose Veins

Information for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy?

What are spider veins? What is the best treatment for spider veins?

Femoral artery bypass graft (Including femoral crossover graft)

Recurrent Varicose Veins. Vineet Mishra, MD Director of Mohs Surgery and Procedural Dermatology University of Texas Health Science Center San Antonio

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis

T.E.D. Anti-Embolism Stockings

Renovascular Hypertension

Humulin (LY041001) Page 1 of 1

Varicose Vein Surgery Criteria Access Based Protocol Supporting people in Dorset to lead healthier lives

To provide standardized Supervised Exercise Programs across the province.

PRACTICE PROBLEMS FOR BIOSTATISTICS

Clinical Medical Policy Varicose Vein Treatment

THE RELATIONSHIP BETWEEN PATIENT STATUS AND RECURRENCY RATE FOLLOWING LASER SURGERY OF VARICOSE VEINS

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Preventing Blood Clots in Adult Patients. Information For Patients

Sponsor Novartis Pharmaceuticals

SEDICO Newsletter Issue 8. Varicose veins

VARICOSE VEINS. Information Leaflet. Your Health. Our Priority. VTE Ambulatory Clinic Stepping Hill Hospital

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension

Donor Adverse Events

V03 Varicose Veins Surgery

Deep Vein Thrombosis (DVT) in pregnancy

Treatment by LASER. Understanding Varicose veins and. Dr. Rajesh Mundhada (MD. DNB) Dr. Atul Rewatkar (MD)

Y O U R S U R G E O N S. choice of. implants F O R Y O U R S U R G E R Y

Varicose Veins: Causes, Symptoms and Management. Andrew C. Stanley MD Section of Vascular Surgery

The Treatment of Varicose Veins and Spider Veins

MINISTERIO DE SALUD PUBLICA DIRECCION PROVINCIAL DE SALUD DEL GUAYAS HOSPITAL DE INFECTOLOGIA DR. JOSE DANIEL RODRIGUEZ MARIDUEÑA Guayaquil - Ecuador

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Parametric and non-parametric statistical methods for the life sciences - Session I

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

All patients presenting to the Emergency Department with symptoms suggestive of

Clinical Study Synopsis

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease. Erich Minar Medical University Vienna

Venefit treatment for varicose veins

MEDICAL COVERAGE POLICY SERVICE: Varicose Veins of the Lower Extremities. SERVICE: Treatment of Varicose Veins of the Lower Extremities

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

CMS Limitations Guide - Radiology Services

Marc A. Cohen, MD, FAAOS, FACS Diplomate American Board of Spinal Surgery Fellow American College of Spinal Surgery

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

Measure #420: Varicose Vein Treatment with Saphenous Ablation: Outcome Survey National Quality Strategy Domain: Effective Clinical Care

Do you have any of these varicose vein symptoms?

Title Use of rivaroxaban in suspected DVT in the Emergency Department Standard Operating Procedure. Author s job title. Pharmacist.

The challenge of herpes

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource

Atrial Fibrillation The Basics

Venous thromboembolism: reducing the risk. Quick reference guide. Issue date: January 2010

Transcription:

Studio prospettico, randomizzato monocentrico per il trattamento sintomatico dell insufficienza venosa cronica degli arti inferiori in pazienti trattati con calze preventive con filato SpikEnergy rispetto a pazienti trattati con calze preventive standard (Studio SEVI). A prospective, randomized, monocentric study on chronic venous insufficiency s symptoms treatment with compressive pantyhose with SpikEnergy yarn versus compressive standard stocking: the SEVI Study. INTRODUCTION Chronic venous insufficiency is a common disease that affects a huge part of the population (10-40% of adults), in particularly in female subgroup. Limb compression using graduate compressive socks and pantyhose is widely recommended as cardinal treatment of the symptoms of chronic venous insufficiency in cases of low-moderate insufficiency that are not candidate to surgery. SpikEnergy is a yarn made of copper, silicon and zinc that creates a low electromagnetic 300 microampere 4/10 nanotesla camp that as previously been tested in orthopaedic tutors with good results in terms of pain relieve and tolerability. The aim of this study is to evaluate the efficacy, easy of use and the results on venous insufficiency obtained whit a system consisting in 18 mmhg compressive pantyhose that contain SpikEnergy yarn when compared to common 18 mmhg compressive pantyhose that are usually prescribed in these kind of patients. METHODS The study was a prospective, randomized clinical trial performed in one single centre specialized in venous insufficiency evaluation and treatment. The study included 40 consecutive female patients who underwent clinical evaluation for venous insufficiency and that presented a superficial venous insufficiency classified as low-moderate, in absence of deep or superficial venous thrombosis or phlebostatic ulcers. Within 7 day from the screening visit, all the patients had to do a pregnancy test except for those already in menopause, and only those with negative test were enrolled.

At the first enrolment visit each patient was submitted to a complete physical examination that included the evaluation of oedema with the registration of ankle, calf and thigh circumference and the evaluation of venous insufficiency clinical signs such as varicose veins or the presence of teleangectasias. Anamnesis was performed, to evaluate inclusion and exclusion criteria, other comorbidities, the presence of allergies and the concomitant use of other medicines. Each patient was then submitted to ultrasonographic evaluation and to a series of questionnaires about the symptoms, using a numerical analogue scale (varying from 0 to 10) to evaluate pain, itch, burning and to assess the alteration of the quality of life concerning the venous insufficiency. Then an automatic computed randomization was performed; 20 patients received common pantyhose and were denominated Standard Group (ST), while the other 20 received pantyhose with SpikEnergy yarn and were denominated SpikEnergy Group (SP). The SpikEnergy pantyhoses were create cappello (Prof. Dotti?) su come hanno creato la calze, il campo elettromagnetico, I macchinari per la corretta calibratura di entrambi I modelli di calze. Both the groups were instructed to wear the system for at least 8 hours per day and to immediately contact the investigators in case of adverse events. At the 1 month (± 7 days) follow-up visit, each patient was submitted to the physical examination and to the symptoms questionnaires; moreover, a questionnaires regarding the tolerability, mobility and general satisfaction of the patient about her stocking system was compiled (possible assessments were excellent, good, satisfactory, poor or insufficient). At the 6 months (± 14 days) follow-up visits, each patient was submitted to the same kind of visit as the 1 month follow-up and was also submitted to ultrasonographic evaluation of the venous insufficiency level. Study enrolment started on May 12, 2011, the enrolment period was of 6 month, and the study ended on may 14, 2012. Inclusion criteria were: -age > 18 years -informed consent -patient C1-3, Ep,s, As,p, Pr, according to CEAP classification -patients able to wear compressive stocking system

Exclusion criteria were: -pregnancy -other classes of CEAP classification -use of phlebotonic drugs -limb arteriopathy -high risk of deep venous thrombosis -thrombophilic patients -hyperhomocysteinemia -allergy to the device s materials -neuropathy -cutaneous infection Primary end points were the reduction of oedema and the reduction of symptoms, in particularly pain, itch, burning and the improvement of quality of life, assessed with numeric analogue scales (NAS), and the eventual improvement of venous insufficiency evaluate with duplex scan. Secondary end points were the tolerability of the stocking system, the easy to use and mobility granted by the system and the general satisfaction of the patient. Statistical analysis was performed and data were presented as a distribution of continuous variables (mean, median, lower and higher value and standard deviation) and as frequency of categorical variables (absolute value and percentage); 95% confidence intervals were calculated. Frequencies were analysed with χ 2 testing or with exact Fisher s test, with t-test was used to evaluate normally distributed linear variables, or the Wilcoxon test. A p value < 0.05 has been considered statistically significant, and all the tests had two tails. RESULTS The study included an homogenous cohort of 40 female patients whose CEAP classification was C2,3, Ep, As, Pr. Three patients (7,5%) matched exclusion criteria of previous venous surgery but only for one leg while the other leg matched inclusion criteria, so it was considered a minor violation and the patients were included in the study.

The anthropometric characteristics in the two groups were not significantly different. Spikenergy (SP) Standard (ST) All Age (years) Mean 44.87 43.27 44.07 Median 44.51(31.59-62.21) 44.26 (26.33-63.61) 44.28 (26.33-63.61) Height (cm) Mean 164.25 164.55 164.40 Median 163.50 (152-185) 163.50 (150-182) 163.50 (150-185) Weight (kg) Mean 64 63.05 63.53 Median 64 (48-88) 58 (45-104) 62 (45-104) BMI Mean 23.74 23.17 23.46 Median 23.91 (17.63-30.47) 21.55 (18.03-33.96) 23.26 (17.63-33.96) As in general population, the percentage of patients with a family history of cardiovascular disease was high (30/40 patients, 75%), while other comorbidities were well distributed. Spikenergy (SP) Standard (ST) All Family History OF CVD 14 (70%) 16 (80%) 30 (75%) Smoking 2 (10%) 7 (35%) 9 (22.5%) Obesity 5 (25%) 6 (30%) 11 (27.5%) Dyslipidemia 5 (25%) 3 (15%) 8 (20%) Hypertension 1 (5%) 3 (15%) 4 (10%) CAD 0 0 0 COPD 0 0 0 Allergies 9 (45%) 8 (40%) 17 (42.5%) The pantyhose was correctly worn from all the patients during the entire study period, none of the patient stopped the study and all the patients regularly presented at the 1 month and 6 months follow-up visit. None adverse event was observed during the study. Thirty-eight patients (95%), presented at baseline visit with ankle oedema, so ranging C3 in CEAP classification. Comparing circumferences changes between baseline and 1 month follow-up, we observed a mean 0,20 cm reduction of ankle circumference in the SP group as well as in the ST group (t value 0, p 1.0000), a mean 0,23 cm reduction of calf circumference in the SP group versus an absence of variation in the ST group (t value -0.811, p 0.4223) and a

mean 0,33 cm reduction of thigh circumference in the SP group versus a mean 0,10 cm increase in the ST group (t value -0.721, p 0.4752). Comparing circumferences changes between baseline and 6 months follow-up, we observed a mean 0,40 cm reduction of ankle circumference in the SP group and a mean 0,30 cm reduction in the ST group (t value -0.375, p 0.7096), a mean 0,73 cm reduction of calf circumference in the SP group versus a mean 0,18 cm increase in the ST group (t value -2.590, p 0.0135) and a mean 0,63 cm reduction of thigh circumference in the SP group versus a mean 0,55 cm reduction in the ST group (t value -0.096, p 0.9243). Comparing symptoms, at 1 month pain reduced from a mean 3.40 to a mean 3.30 value in SP group and from a mean 5.2 to a mean 3.25 value in the ST group, itch increased from

a mean 1.70 to a mean 4.35 value in the SP group and reduced from a mean 2.05 to a mean 1.95 value in the ST group, burning reduced from a mean 2.40 to a mean 2.30 value in the SP group while it reduced from a mean 3.20 to a mean 1.35 mean value in the ST group. Concerning the assessment of quality of life improvements, we observed an increase from a mean 7.55 to a mean 7.75 value in the SP group and an increase form a mean 6.60 to a mean 8.40 value in the ST group. Comparing baseline and 6 month results, pain ad a mean 0.40 reduction in the SP group versus a mean 1.30 increase in the ST group (t value 2.1280, p 0.0355), itch had a mean increase of 1.80 in the SP group versus a mean reduction of 0.05 in the ST group (t value 1.950, p 0.0586), burning had a mean 0.35 increase in the SP group and had a mean 1.05 reduction in the ST group (t value 1.332, p 0.1906), while quality of life had a mean 0.15 increase in the SP group versus a mean 1.55 increase in the ST group (t value -1.942, p 0.0596). Analyzing duplex scan findings at baseline, we observed that none of the patient presented with deep venous thrombosis, that was also an exclusion criteria; in most of the cases the venous insufficiency was due to saphenous-femoral ostium or internal

saphenous vein incompetence, only in 4 legs we observed saphenous-popliteal and external saphenous vein incompetence. At 6 month follow-up, in the SP group we observed incompetence worsening only in 1 case (only in one leg), passing from a normal continence to mild incompetence of the saphenous-femorale ostium; instead we observed worsening in 4 cases in the standard group: 1 passing from a normal continence to mild incompetence of the saphenousfemorale ostium (only in one leg), 1 passing from normal continence to mild incompetence of the internal saphenous vein (only in one leg), 1 passing from normal continence to mild incompetence of the saphenous-popliteal ostium (only in one leg) and 1 passing from from normal continence to mild incompetence of the external saphenous vein (only in one leg). None improvement in the ultrasonographic findings was observed in both the two groups. Comparing the tolerability, mobility granted by the device and the general satisfaction, the tolerability in the SP group was considered insufficient/poor in 4 cases, satisfactory in 9 cases and good/excellent in 7 cases at 1 month, while in the ST group it was assessed insufficient/poor in 0 case, satisfactory in 2 cases and good/excellent in 18 cases (p 0.0013). At 6 month the tolerability in the SP group was considered insufficient/poor in 4 cases, satisfactory in 10 cases and good/excellent in 6 cases, while in the ST group it was assessed insufficient/poor in 0 cases, satisfactory in 3 cases and good/excellent in 17 cases (p 0.0015). The mobility granted by the stocking in the SP group was considered insufficient/poor in 1 case, satisfactory in 7 cases and good/excellent in 12 cases at 1 month, while in the ST group it was assessed insufficient/poor in 1 case, satisfactory in 3 cases and good/excellent in 16 cases (p 0.3377). At 6 month the mobility in the SP group was considered insufficient/poor in 2 cases, satisfactory in 6 cases and good/excellent in 12 cases, while in the ST group it was assessed insufficient/poor in 1 case, satisfactory in 4 cases and good/excellent in 15 cases (p 0.5866). The general satisfaction in the SP group was considered insufficient/poor in 2 cases, satisfactory in 9 cases and good/excellent in 9 cases at 1 month, while in the ST group it was assessed insufficient/poor in 1 case, satisfactory in 1 case and good/excellent in 18 cases (p 0.0077). At 6 month the general satisfaction in the SP group was considered insufficient/poor in 3 cases, satisfactory in 8 cases and good/excellent in 9 cases, while in the ST group it was assessed insufficient/poor in 2 case, satisfactory in 3 cases and good/excellent in 15 cases (p 0.1372).

6 As collateral results, interviewing the patients we observed that those of SP group noticed an improvement in skin aspect and a slight reduction in cellulitis, suggesting a potential role of the electromagnetic camp on this aspect, that could be well investigated in the future. CONCLUSIONS The compressive pantyhose with SpikEnergy yarn seems to be safe; no adverse event was observed during the study not even in those that presented allergy to metals. Analyzing result, we observed a significant reduction of circumference at calf level in the SP group, in the other cases the differences were not statistically significant. Concerning on symptoms, a statistically significant reduction of pain in SP group was observed; however, a significant increase in itch was observed, and in some cases it was

evident that the itch was more due to the electromagnetic camp than to venous insufficiency (it disappeared at socks removal). Only slight and not statistically significant differences were observed in ultrasonographic findings, and is important to stress that none of the patient improved during the study, because obviously elastic compression treats the symptoms but can not improve venous valvular incompetence. The most significant information that emerges from the study is about the tolerability and the general satisfaction of the patient, that are significantly poorer in the SP group. Obviously the study is only on a small group of patients; future studies on larger group, eventually groups including also patient with phlebostatic ulcers or venous thrombosis could better understand the role of electromagnetic camp in venous insufficiency; probably it could be useful to test devices with a lower electromagnetic camp that can be more comfortable for the patients.